Lilly Alzheimer’s Drug Slows Mental Decline, Study Finds

Eli Lilly & Co.’s experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by about 30 percent, offering the first evidence that a medication may hamper the course of the ailment, researchers said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.